C
hronic liver disease is a major health problem in the world, and it is the 12th cause of death in the United States, with a rate of 12.5 per 100,000 inhabitants. 1 Viral hepatitis, nonalcoholic fatty liver disease, and alcoholic liver disease account for most chronic liver disease. Liver fibrosis, which may lead to cirrhosis and its complications if the cause of the liver injury is left untreated, is the hallmark of all of them. Nowadays, shear wave elastographic (SWE) techniques have brought a substantial reduction of liver biopsies performed to stage liver fibrosis in patients with chronic hepatitis. Indeed, in several clinical scenarios, rather than an exact histologic staging of liver fibrosis, it is important to identify patients with substantial fibrosis because they may need treatment and those with severe fibrosis or cirrhosis because they need follow-up. 2 On the other hand, the spectrum of fibrosis is a continuum; thus, for asymptomatic patients with severe fibrosis or liver cirrhosis at an early stage, the term "compensated advanced chronic liver disease" has been proposed. 3 Shear wave elastographic techniques for the assessment of liver elasticity are based on the generation of shear waves by an external or internal mechanical push. 4, 5 Transient elastography (TE) is an SWE technique in which a mechanical external controlled vibration generates shear waves that propagate into the liver. It is performed with a dedicated device, the FibroScan (Echosens, Paris, France), which does not provide a morphologic image of the liver. With the SWE techniques incorporated in ultrasound (US) systems, the shear waves are produced by the acoustic push of the US beam directly into the liver. They are termed acoustic radiation force impulse (ARFI) techniques. An assessment of the shear wave speed can be made either at one point, as in point SWE (pSWE), or by means of several ARFI lines, it is possible to obtain quantitative images of the shear wave speed as in 2-dimensional (2D) SWE. [4] [5] [6] Unlike the FibroScan, which is a device dedicated to the assessment of liver stiffness, the ARFI techniques are implemented in the US systems; thus, it is possible to perform a morphologic evaluation of the liver with B-mode imaging, a blood flow evaluation using Doppler US, and an assessment of the mechanical properties of the liver (ie, the stiffness estimate) at the same time. In most countries outside North America, the point SWE and 2D SWE techniques are performed either by hepatologists/gastroenterologists or by radiologists, whereas TE is the only technique that could be performed also by a nurse, and it is not generally present in a radiology laboratory.
Guidelines and Recommendations
The availability of accurate noninvasive methods for the assessment of liver fibrosis was an important breakthrough and has prompted US federations of societies as well as clinical and radiologic societies to issue international guidelines or consensus statements on the clinical applications of the SWE techniques. 4, 5, [7] [8] [9] [10] [11] This article is a review of the most important guidelines that have been released as of today.
European Federation of Societies for Ultrasound in Medicine and Biology Guidelines
The European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) produced guidelines and recommendations on the clinical applications of US elastography in 2013. 7 The largest section of the document was dedicated to the liver and was mainly based on the published TE studies because of the great experience with this technique, which had been available for almost a decade at that time.
In 2017, an update of the guidelines, focused on the clinical use of the SWE techniques in the assessment of diffuse liver disease, was released. 5 The document analyzes the role of SWE techniques in different etiologies of liver diseases and in several clinical scenarios. All of the recommendations were judged according to the Oxford Center for Evidence-Based Medicine. The correct terminology was clarified, and the differences between US systems were analyzed.
For all of the available techniques, the highest level of evidence was in patients with chronic viral hepatitis, and TE was still the most validated technique. The guidelines recommend that TE, point SWE, and 2D SWE techniques can be used as first-line tools for assessing the severity of liver fibrosis in patients with chronic viral hepatitis, and their best performance is in ruling out cirrhosis in patients with chronic hepatitis C and in identifying patients with cirrhosis in chronic hepatitis B cases. With the use of direct-acting antiviral agents for the treatment of chronic hepatitis C, a dramatic and rapid decrease of liver stiffness values, which is likely due to a decrease of inflammation, has been observed. Thus, SWE techniques are not recommended to monitor fibrosis changes during treatment with direct-acting antiviral agents because the cutoffs and the interval for identifying cirrhosis regression have yet to be defined. For other etiologies of liver disease, most studies have been performed with TE; thus, no recommendation has been made regarding the use of the ARFI techniques.
World Federation for Ultrasound in Medicine and Biology Guidelines
In 2015, the World Federation for Ultrasound in Medicine and Biology (WFUMB) released guidelines for the use of elastographic techniques in liver disease. 8 The first consensus meeting of elastography experts from around the world was held in March 2013 in Washington, DC. The recommendations were based on the international literature and on the expertise of the team designated by WFUMB; however, no grading system was adopted because it was thought that there was great heterogeneity between studies, and the available evidence was still low. The document was clinically oriented and was aimed at assessing the value of elastography in the management of liver diseases. The usefulness of strain elastography, which is mainly used in Far East countries, was also analyzed. It was pointed out that the positive results obtained with strain elastography in the Japanese series were not confirmed in the European series. In the document, the recommendations were also given as answers to standard questions. In 2018, WFUMB thought the need to update the document. each recommendation was judged according to the Oxford Centre for Evidence-Based Medicine. The document reviews the several US-based elastographic techniques available and has a clinical perspective. As in the update of the EFSUMB guidelines for liver elastography, the correct terminology, the differences between systems, as well as the technical procedures and limitations are discussed. The use of SWE techniques in pediatric patients and for the evaluation of focal liver lesions is also analyzed; however, no recommendation is given because of the low level of evidence in the literature.
A paragraph is dedicated to spleen stiffness measurement, which has been proposed as an additional tool for the evaluation of portal hypertension, but no recommendation is given because further studies are needed before including it in the diagnostic workup of cirrhotic patients. What is new with respect to other sets of guidelines is a section dedicated to the assessment and grading of liver steatosis. Even though they are not performed with an SWE technique, the experts thought that it was a very hot topic because of the high prevalence of nonalcoholic fatty liver disease in the world. As of today, the studies have been conducted using the controlled attenuation parameter, which is available on the FibroScan system. It is agreed that, even though that parameter is promising for detecting liver steatosis, there is a large overlap between adjacent grades in the quantification of steatosis, and there are no consensual cutoff values.
Society of Radiologists in Ultrasound Consensus Statement
In 2014, the Society of Radiologists in Ultrasound convened a panel of specialists from radiology, hepatology, pathology, and basic science and physics to elaborate a consensus regarding the use of elastography in the assessment of liver fibrosis in chronic liver disease. 4 The consensus conference statement, published in 2015, included all of the available elastographic techniques, listing the advantages and disadvantages of each, as was done a few years later in the updates of the EFSUMB and WFUMB guidelines, and a defined protocol was recommended for performing the examination. 5, 9 The recommendations in this statement were based on an analysis of the existing literature and on the experience of the expert team. There was a consensus in recommending elastography for identifying patients with no or minimal fibrosis and those with severe fibrosis or cirrhosis rather than pursuing staging of liver fibrosis similar to that obtained by histologic analysis. It was agreed that there is an overlap of stiffness values in the intermediate stage of liver fibrosis; thus, the clinical evaluation should determine the appropriate follow-up and the need for additional tests, including liver biopsy, in these cases. On the other hand, the spectrum of fibrosis is continuous rather than a categorical scale.
The consensus also analyzed the literature about the usefulness of magnetic resonance elastography in the staging of liver fibrosis. In the few studies that were available at that time, magnetic resonance elastography showed higher diagnostic performance than TE; however, the experts agreed that the cost and availability of magnetic resonance elastography needed be considered. At that time, direct-acting antiviral agents were not yet available, and it was thought, based on literature data, that elastography was a useful tool to monitor disease progression and the response to treatment.
The panel underlined that all of the published studies that compared TE and ARFI techniques using liver biopsy as the reference standard reported that the two techniques were at least equivalent, and some studies suggested that ARFI techniques were more accurate than TE for the assessment of liver stiffness. A paragraph was dedicated to the reporting of elastography results, stressing that the patient position and US system used should be specified because it is mandatory to use similar equipment and techniques in subsequent studies of the same patients.
European Association for the Study of the LiverAsociación Latinoamericana Para el Estudio del Hígado Guidelines
In 2015, the European Association for the Study of the Liver, together with the Asociación Latinoamericana Para el Estudio del Hígado, produced clinical practice guidelines for the use of noninvasive tests in the evaluation of liver disease. 10 The evidence and recommendations were graded according to the Grading of Recommendations Assessment, Development, and Evaluation system. It was underlined that the detection of cirrhosis represents the most important clinical end point, independently from the etiology of the chronic liver disease. The role of serum biomarkers of liver fibrosis was also analyzed on the basis of literature data. The advantages of serum biomarkers are high applicability, good reproducibility, and the wide availability of nonpatented markers. It was agreed that none of them is specific for the liver, and the results may be influenced by changes in the clearance and excretion of a single biomarker.
The technical aspects related to the use of TE were discussed, underlining operator experience and correct interpretation of the results. It was stated that the main limitation of the technique is the impossibility of obtaining results in cases of ascites and the limited applicability in cases of obesity. The guidelines indicate that, for a stiffness assessment, TE should be considered the reference standard. Indeed, TE was the first SWE technique available on the market; thus, it is the most validated one. Nonetheless, the European Association for the Study of the Liver-Asociación Latinoamericana Para el Estudio del Hígado guidelines recognize that the point SWE and 2D SWE techniques have the same accuracy as TE for the staging of liver fibrosis, even though the level of available evidence was lower than that for TE at that time.
Asian-Pacific Association for the Study of the Liver Guidelines
In 2016, the Asian-Pacific Association for the Study of the Liver developed consensus guidelines on the assessment of liver fibrosis that included invasive methods, such as liver biopsy and hepatic venous pressure gradient measurements, and noninvasive methods, such as biomarkers, conventional radiologic methods, and elastographic techniques. 12 Experts reviewed the published literature, and the Oxford Center for Evidence-Based Medicine's system was used for the consensus statements. In these guidelines, liver biopsy was considered the reference standard; however, all of the limitations of the procedure were highlighted. In the short paragraph dedicated to elastographic techniques, it was acknowledged that ARFI-based methods are as accurate as TE in staging liver fibrosis.
American Gastroenterological Association Guidelines
The guidelines for the use of elastography in the evaluation of liver fibrosis released by the American Gastroenterological Association (AGA) are a step forward to the acceptance of this technique by clinicians in North America and were very much needed. 11 In North America, since the clearance of the SWE techniques by the US Food and Drug administration in 2013, the TE technique has been used mostly by clinicians, mainly hepatologists/gastroenterologists, whereas the ARFI techniques have been used mostly by radiologists.
These guidelines are focused on the use of TE, and the literature regarding the use of the ARFI-based techniques was not analyzed. According to the Grading of Recommendations Assessment, Development, and Evaluation method, all recommendations about the use of TE were graded conditional and with lowquality evidence.
Comments
The use of noninvasive techniques has allowed the diagnosis of suspected liver cirrhosis at an early stage. Before the availability of them, such a diagnosis was possible only with liver biopsy, ie, an invasive procedure with some limitations and risks of complications and with related costs, which has not been well accepted by patients. Also, for these reasons, the availability of SWE may permit better care of patients who previously refused to undergo liver biopsy for fibrosis staging.
Several technical issues related to the SWE techniques have been addressed by the guidelines, including terminology, confounding factors, and limitations.
All guidelines recommend a strict protocol to obtain accurate measurements. As reported in the Society of Radiologists in Ultrasound consensus conference statement and in the update of the WFUMB guidelines, several studies have shown that, for all the available US SWE techniques, the most important quality criterion for a valid measurement is an interquartile range-to-median ratio of the 30% or less for the acquisitions. 4, 9 The accuracy of the measurement improves when this criterion is fulfilled.
When SWE techniques are used, it is well known that intersystem variability should be taken into account. 13, 14 In a study that compared the results obtained with 6 different US systems using the FibroScan as a reference, it was shown that the agreement between measurements performed with different systems was good to excellent, and the overall interobserver agreement was greater than 0.90 in expert hands. 13 However, high concordance merely indicates that the values follow the same direction and not that the absolute values are the same. Thus, for the staging of liver fibrosis with SWE, the cutoff liver stiffness values could not be used interchangeably across different US systems. Moreover, it should be kept in mind that the cutoff values used to estimate the presence and severity of liver fibrosis are related to the etiology of the liver disease. Thus, the cutoffs are system specific and are related to the etiology of the underlying liver disease.
In the AGA guidelines, it is claimed that TE is the most commonly used imaging-based technique for fibrosis assessment in the United States; however, no evidence is provided; thus, this statement could be misleading. The ARFI-based techniques received US Food and Drug Administration approval after TE and therefore have been on the market for a shorter time; nonetheless, approximately 25% of all mid-and high-range US systems in the United States are now purchased with ARFI liver software, and in countries where both TE and ARFI-based techniques have been available for a longer time, the ARFI techniques have also been recommended. 15 For the patient's benefit, the AGA cannot ignore the fact that, in addition to TE, other elastographic techniques are widely available in the United States, and plenty of studies have assessed their value and have shown that the accuracy of these techniques is equal or superior to that of TE. 5, [7] [8] [9] [10] 16, 17 The title of the AGA guidelines implies that the role of elastographic techniques in the evaluation of liver fibrosis is addressed, even though only the literature related to TE was analyzed, and the recommendations are on the use and role of TE for fibrosis staging. Indeed, elastography cannot be identified with TE, and, also for that reason, the AGA guidelines are not well balanced. In fact, the growing amount of evidence on the use of the ARFI techniques is overlooked, and it is not even mentioned that all of the published studies have shown that these techniques have accuracy that is at least similar to that reported for TE. It should be acknowledged that TE is a pointof-care technique, available in the hepatologist's office. However, the FibroScan is a dedicated device and is not able to evaluate liver morphologic characteristics. The ARFI-based techniques are implemented in US systems; thus, among their advantages is the fact that a thorough evaluation of the liver can also be performed so that a possible concomitant liver lesion is not overlooked.
Conclusions
1. As of today, several guidelines on the use of noninvasive methods for the assessment of chronic liver disease have been released. 2. All of guidelines have accepted the use of SWE techniques as substitutes for liver biopsy for fibrosis staging in adult patients with chronic viral hepatitis. The level of evidence for other etiologies of liver disease is still low; however, the studies conducted thus far agree that these techniques show good performance for the assessment of liver cirrhosis when confounding factors are taken into account. 3. Transient elastography and ARFI-based techniques have the same accuracy for the assessment of liver stiffness; however, some studies suggested that the ARFI techniques were more accurate than TE. 4. When performing SWE studies, the use of quality criteria may improve the accuracy of measurements. 5. In the era of direct-acting antiviral agents for the treatment of chronic hepatitis C, the previous cutoffs for the staging of liver fibrosis should not be used when a patient has achieved a sustained virologic response.
